|

HB1801 Clinical Trials

4 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1Phase 3: 3

Top Sponsors

  • Shanghai JMT-Bio Inc.3
  • Fudan University1

Indications

  • Breast Cancer4
  • Cancer4
  • Resectable HER2-positive Breast Cancer1
  • Early or Locally Advanced HER2-positive Breast Cancer1
  • Hormone Receptor Negative Tumor1

Other4 trials

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Phase 3
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.